Our Industry Partners
Technological progress in biomedical research and our knowledge of human diseases are constantly increasing. The translation of research results into new therapies is not. Industry and academia agree that new approaches in biomedical research are needed to make results reproducible and finally applicable for the benefit of patients.
The BioMed X, located in the campus of top universities or within pharmaceutical company incubators, enables a completely new way to accelerate the pace of innovation at which big challenges in biomedical research are tackled.
A Partnership with BioMed X offers you:
- The ideal combination of free, creative, curiosity-driven research with a solid validation of results, timelines and deliverables
- The outsourcing of biomedical research in high-risk exploratory fields
- A cost-effective solution with a clear exit strategy based on IP ownership and transfer of all data and materials
- Internalization of successfully finished research projects into any development pipeline
- Access to the best academic research talent via the BioMed X Career Space
- The opportunity to gather novel ideas from the Global Scientific Community
- A collaborative working model, focused on clear deliverables and constant progress leveraging partners´expertise
- Benefit from open-innovation lab facilities on the campuses of top universities or pharmaceutical company incubators
- Easy communication with team, reagent and expertise sharing with monthly update calls, ad hoc calls, Joint Steering Committees progress reports twice per year
Our Partners at a Glance
AbbVie joined BioMed X as a partner in 2014 and has been supporting the following research projects:
Boehringer Ingelheim joined BioMed X as a partner in 2014 and has been supporting the following research projects:
- Epigenetics and COPD
- Brain Microcircuits in Psychiatric Diseases
- Pathogen-Mediated Modulation of Innate Immunity
- Early Intervention in Psychiatric Diseases
- Advanced Biomarker Detection for Pharmacological Monitoring in the Brain
- Next-Generation Clinically Relevant Models of Fibrosis and Wound Healing
- New Platform for Next-Generation Intraocular Biologics
Daiichi Sankyo joined BioMed X as a partner in 2025 and is supporting the following research project:
Gates Foundation joined BioMed X as a partner in 2025 and is supporting the following research project:
Johnson & Johnson joined BioMed X as a partner in 2015 and has been supporting the following research projects:
Merck KGaA was the first partner to join BioMed X in 2013 and has been supporting the following research projects:
- Metabolism and Signaling in Cancer
- Selective Kinase Inhibitors
- Immunosuppressive Microenvironment of Tumors
- DNA Damage in Cancer
- RNA Splicing in Cancer
- Intestinal Epithelial Barrier in Autoimmune Diseases
- Tracing Immune Cell Dysfunction in Autoimmunity and Neuroinflammation
- Extrachromosomal DNA in Cancer
- Synthetic Lethality in DNA Repair
- New Strategies to Enhance the Immunogenicity of Tumors
Novo Nordisk joined BioMed X as a partner in 2025 and is supporting the following research project:
Ono joined BioMed X as a partner in 2023 and is supporting the following research project:
Roche Diagnostics joined BioMed X as a partner in 2014 and has been supporting the following research project:
Sanofi joined BioMed X as a partner in 2022 and is supporting the following research project:
Servier joined BioMed X as a partner in 2023 and is supporting the following research projects: